Mogadon (Nitrazepam)

Nitrazepam, the active ingredient in Mogadon, is a benzodiazepine presented as an oral tablet for oral use. It is indicated for short‑term treatment of severe insomnia and may be used off‑label for anxiety or as an adjunct in certain seizure disorders.

GNH USA supplies Mogadon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nitrazepam acts on the central nervous system to facilitate sleep and reduce anxiety, primarily through modulation of GABA‑A receptors.

- Severe insomnia: helps initiate and maintain sleep during short‑term therapy. - Anxiety disorders (off‑label): may alleviate acute anxiety symptoms. - Certain seizure disorders (off‑label): used as an adjunct to control seizures in specific cases.

Nitrazepam may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Fatigue: reduced energy and motivation. - Dizziness: sensation of light‑headedness or unsteadiness. - Impaired coordination: difficulty with fine motor tasks. - Memory impairment: short‑term recall problems. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Depression or suicidal thoughts: mood changes requiring immediate attention. - Respiratory depression: slowed breathing, especially with other depressants. - Severe skin reactions: rash, Stevens‑Johnson syndrome. - Paradoxical agitation: increased anxiety or aggression. - Dependence and withdrawal seizures: risk with prolonged use. - Hepatic dysfunction: abnormal liver enzymes.

When prescribing Nitrazepam, clinicians should assess patient risk factors and monitor for adverse outcomes.

- Assess severity: confirm that insomnia is severe and warrants pharmacologic therapy. - Evaluate mental health: screen for depression or suicidal ideation before initiating treatment. - Avoid abrupt discontinuation: taper the dose to reduce withdrawal risk. - Use caution in elderly: increased sensitivity to sedation and falls. - Contraindicated in pregnancy: category D indicates potential fetal harm. - Store at ambient temperature: keep in the original container, protect from moisture.

Nitrazepam can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Alcohol: additive CNS depression leading to profound sedation. - Opioids: increased risk of respiratory depression and profound sedation. - Other benzodiazepines: cumulative sedative effects and heightened dependence risk. - Azole antifungals (e.g., ketoconazole): inhibit metabolism, raising nitrazepam levels. - Macrolide antibiotics (e.g., erythromycin): may increase plasma concentrations.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): may enhance sedative effects. - Antihistamines: additive drowsiness. - Antihypertensives: potential for orthostatic hypotension. - Carbamazepine: enzyme induction may reduce nitrazepam efficacy. - Cimetidine: may modestly increase nitrazepam levels.